Skip to main content
SpringerLink
Log in

Prostate cancer

A closer look at the initial results from the REDUCE trial

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Initial results of the REDUCE trial suggest that dutasteride decreases the incidence of prostate cancer in men with persistently elevated PSA; however, questions have emerged about the drug's effect on the incidence of high-grade cancer. Adjustment for post-randomization confounders, however, brings the true benefit of this drug into clearer focus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Attempts to adjust for the effect of dutasteride on serum PSA in clinical trials can introduce important biases.

References

  1. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202 (2010).

    Article  CAS  Google Scholar 

  2. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).

    Article  CAS  Google Scholar 

  3. Fleshner, N. E., O'Sullivan, M. & Fair, W. R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 158, 505–508 (1997).

    Article  CAS  PubMed  Google Scholar 

  4. Cohen, Y. C. et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 99, 1366–1374 (2007).

    Article  CAS  PubMed  Google Scholar 

  5. Pinsky, P., Parnes, H. & Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev. Res. 1, 182–186 (2008).

    Article  Google Scholar 

  6. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev. Res. 1, 174–181 (2008).

    Article  CAS  Google Scholar 

  7. Choo, R. et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4–7, clinically localized prostate cancer? Prostate 67, 1614–1620 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Kramer, B. S. et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27, 1502–1516 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Illinois at Chicago, 840 South Wood Street, Chicago, 60612, IL, USA

    Peter H. Gann

Authors
  1. Peter H. Gann
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gann, P. A closer look at the initial results from the REDUCE trial. Nat Rev Urol 7, 535–537 (2010). https://doi.org/10.1038/nrurol.2010.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.144

  • Springer Nature Limited

Search

Navigation